*UT Southwestern Medical Center, Center for Human Nutrition, Dallas, TX

†Department of Radiation Oncology

‡Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center

§Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

This work was supported by the Burroughs Wellcome Fund Career Awards for Medical Scientists (1019692) and Cancer Prevention Research Institute of Texas (RP200170 and RP230140) and American Cancer Society grant (133889-RSG-19-195-01-TBE); and National Institutes of Health grants (1R01CA266900-01, 1P30DK127984-01A1, P30CA142543).

B.S.G. was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health grants TL1TR001104 and UL1TR001105. P.I. has served as a consultant to Helsinn Therapeutics and AstraZeneca, and Incyte has provided clinical trial funding to UTSW for one of his trials. R.E.I. has received funding from Pfizer for unrelated work. Portions of work related to this manuscript were presented at the American Society for Radiation Oncology 2016 Annual Meeting in Boston, Massachusetts, and the American Society for Clinical Oncology 2016 Palliative Care Symposium in San Francisco, California. The remaining authors declare no conflicts of interest.

Correspondence: Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center 2280 Inwood Road, Dallas, TX 75235. E-mail: [email protected]; Rodney Infante, MD, PhD, UT Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-9041. E-mail: [email protected].

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.